Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Frequently asked questions
What sector does SENSEONICS HLGS.INC.-001 (6L6) operate in?
SENSEONICS HLGS.INC.-001 belongs to the Healthcare sector and operates in the Medical Devices industry.
What is SENSEONICS HLGS.INC.-001 (6L6) current stock price?
As of the latest data, SENSEONICS HLGS.INC.-001 stock price is €5.00, with a previous close of €5.00.
What is SENSEONICS HLGS.INC.-001 (6L6) current market capitalization?
SENSEONICS HLGS.INC.-001 market cap is approximately 204.00 million.
What is SENSEONICS HLGS.INC.-001 (6L6) Earnings Per Share (EPS)?
The trailing EPS is -€1.72.
Does SENSEONICS HLGS.INC.-001 (6L6) pay dividends?
No. SENSEONICS HLGS.INC.-001 does not pay a dividend.
What is SENSEONICS HLGS.INC.-001 (6L6) beta (volatility) score?
SENSEONICS HLGS.INC.-001 has a beta of 0.839, meaning its volatility is roughly in line with the market.